Summarized by Masters of Longevity from PR Newswire.
An AI-focused biotech press release describing a new peptide immunotherapy candidate and the company’s plans to move it into first-in-human studies. It previews what readers can expect about the research approach, preclinical program, and next development steps.
Key Takeaways
- Immorta Bio completed planned preclinical studies for an AI-designed nine–amino-acid peptide called SenoMune‑0257.
- Preclinical data reportedly show SenoMune‑0257 stimulates cytotoxic T cells that selectively eliminate senescent cells under tested conditions.
- The company plans to begin initial human clinical evaluation of SenoMune‑0257 in 2026 with clinical entry anticipated before year-end.
